CMS Modified NCD 95 for Injection Sclerotherapy for Esophageal Variceal Bleeding — What Billing Teams Need to Know in 2026
TL;DR: The Centers for Medicare & Medicaid Services modified NCD 95 governing injection sclerotherapy for esophageal variceal bleeding, with an effective date of March 7, 2026. The policy confirms Medicare coverage under the Physicians' Services benefit category. This policy does not list specific CPT codes.
If your practice performs endoscopic injection sclerotherapy for variceal bleeding, this update touches the CMS injection sclerotherapy coverage policy directly. The change is classified as a modification to NCD 95 in the Medicare National Coverage Determinations system. Here's what the update means for your billing team and where you need to act.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Centers for Medicare & Medicaid Services (CMS) |
| Policy | Injection Sclerotherapy for Esophageal Variceal Bleeding |
| Policy Code | NCD 95 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | Medium |
| Specialties Affected | Gastroenterology, General Surgery, Interventional Endoscopy, Hospital Outpatient, Inpatient Facility |
| Key Action | Confirm your injection sclerotherapy billing aligns with Medicare's Physicians' Services benefit category and verify your MAC has no local restrictions that narrow national coverage |
CMS Injection Sclerotherapy Coverage Criteria and Medical Necessity Requirements 2026
NCD 95 is the National Coverage Determination governing Medicare coverage of injection sclerotherapy for esophageal variceal bleeding. The policy sits under the Physicians' Services benefit category. The coverage statement is direct: this procedure is covered under Medicare.
The procedure itself involves inserting a flexible fiberoptic endoscope into the esophagus. The provider then injects a sclerosing agent or solution directly into the varicosities to control active or recurrent bleeding. That clinical description is the foundation of the coverage policy. Your documentation needs to reflect that clinical reality.
Medical necessity documentation should center on the diagnosis of esophageal varices with bleeding or a high-risk bleeding presentation. CMS does not spell out a detailed list of criteria within NCD 95 beyond confirming coverage, but medical necessity still governs every claim. If the record doesn't show a clinical need for the procedure — active variceal bleeding, prior bleeding episode, or significant bleeding risk — you're exposed at audit.
The policy references Claims Processing Instructions as a cross-reference. That matters. It means the mechanical billing rules — how to code this, what modifiers apply, what documentation supports the claim — live in the processing instructions, not in the NCD text itself. Pull those instructions before you finalize your charge capture approach.
Whether injection sclerotherapy is covered under Medicare for a given patient still depends on proper documentation of the clinical indication. The NCD gives you national coverage, but your Medicare Administrative Contractor can issue a local coverage determination (LCD) that adds criteria on top of what NCD 95 says. Check your MAC's LCD database before the effective date of March 7, 2026, to confirm there are no local restrictions narrowing this national coverage.
Prior authorization is not mentioned as a requirement in NCD 95. That's consistent with how most national coverage determinations work for established surgical and endoscopic procedures. Still, confirm with your specific MAC whether any prior auth requirements apply at the local level.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Injection sclerotherapy for esophageal variceal bleeding (flexible fiberoptic endoscopic approach with sclerosing agent injection) | Covered | Not specified in NCD 95 | Covered under Medicare Physicians' Services benefit category; medical necessity documentation required; check MAC LCD for local additions |
CMS Injection Sclerotherapy Billing Guidelines and Action Items 2026
The NCD 95 modification is live as of March 7, 2026. Here's what your billing team needs to do now.
| # | Action Item |
|---|---|
| 1 | Pull your MAC's current LCD for endoscopic sclerotherapy procedures. NCD 95 establishes national coverage, but your local Medicare Administrative Contractor may have issued an LCD with additional criteria. Billing without checking your MAC's local rules creates claim denial risk even when national coverage exists. |
| 2 | Review the Claims Processing Instructions cross-referenced in NCD 95. The NCD text points directly to Claims Processing Instructions for the mechanical rules on injection sclerotherapy billing. Those instructions govern coding, modifier use, and documentation requirements. Your charge capture setup should reflect whatever those instructions say. |
| 3 | Audit your documentation templates for esophageal variceal sclerotherapy cases. Medicare coverage doesn't eliminate the medical necessity standard. Every claim needs clear documentation: the diagnosis, the clinical indication for the procedure, the technique used (flexible fiberoptic endoscope, sclerosing agent injection), and the clinical outcome. Weak documentation is the most common reason a covered service still gets denied. |
| 4 | Confirm benefit category assignment on your claims. NCD 95 places this service under Physicians' Services. Claims routed under the wrong benefit category can generate a claim denial even when the service itself is covered. Verify your billing system assigns the correct benefit category for injection sclerotherapy claims. |
| 5 | Flag this for your gastroenterology and surgery billing leads before processing claims dated on or after March 7, 2026. This modification changes the policy version on record. If your team uses policy citations in appeals or prior auth letters, update those references to NCD 95 version 1 (policy key: 95-v1) with the current effective date. |
| 6 | Confirm prior authorization requirements with your MAC. NCD 95 doesn't require prior auth at the national level. But some MACs have local policies that do. A quick check before a patient's procedure is scheduled protects your reimbursement and avoids the administrative burden of a retroactive denial. |
The real issue here is not whether this procedure is covered — it is. The billing risk comes from the gap between national coverage and local execution. NCD 95 is a permissive policy, but permissive policies still generate denials when documentation is thin or billing rules aren't followed precisely.
If your practice has a high volume of esophageal variceal cases, talk to your compliance officer before finalizing your charge capture approach for claims on or after March 7, 2026. The policy text is brief, but the downstream billing guidelines tied to the Claims Processing Instructions cross-reference deserve a close read.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Injection Sclerotherapy Under NCD 95
A Note on Code Data for NCD 95
The policy data published with NCD 95 (policy key: 95-v1, effective March 7, 2026) does not list specific CPT, HCPCS Level II, or ICD-10-CM codes. This is not unusual for older NDCs that predate CMS's current code-mapping practices. The billing guidelines and code-level specifics are housed in the Claims Processing Instructions cross-referenced within the policy.
Do not rely on this NCD alone to set up your charge capture. The absence of explicit codes in NCD 95 means your billing team needs to source the applicable procedure codes from CMS's Claims Processing Instructions directly and verify them with your MAC.
What to Pull from CMS Claims Processing Instructions
For injection sclerotherapy for esophageal variceal bleeding, the relevant procedure codes typically fall in the endoscopy range of the CPT code set. Your MAC's Claims Processing Instructions will identify the exact codes CMS recognizes for this service. Pull those instructions and map them to your charge master.
ICD-10-CM diagnosis codes for esophageal varices with bleeding are standard documentation requirements. Your clinical coders should assign the correct diagnosis code based on the documented clinical presentation. Again, verify the specific codes your MAC expects to see on these claims — don't assume based on general coding references.
If your billing team or compliance officer needs the specific codes for injection sclerotherapy billing and can't locate them in the Claims Processing Instructions, contact your MAC's provider outreach line directly. They can confirm what CMS expects on these claims.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.